In Vitro Nephrotoxicity Services

Eurofins Discovery’s multiplexed nephrotoxicity services provide an effective in vitro cell-based screening model to assess the nephrotoxicity potential of compounds in cells derived directly from human kidney tissue.
 
Our services are especially valuable because if not correctly assessed during lead optimization, drug candidates with undesired safety issues may progress through clinical development and eventually result in high-cost failures. Drug-induced nephrotoxicity is one such safety assessment that can and should be evaluated during earlier stages of drug discovery to determine a compound’s potential to induce kidney-specific injury.
 
Our in vitro cell-based toxicity assays mimic in vivo tissue studies and, in turn, provide a reliable tool for safety evaluation in early stages of drug discovery. We offer two image-based High Content Analysis (HCA) assays using human renal proximal tubule epithelial cells (HRPTEpiC). These multi-endpoint analyses provide a highly sensitive and thorough assessment of nephrotoxicity, which also enables detailed mechanistic information underlying the observed toxicity.